MedTrace Logo

Unscheduled Hospital Readmission After Crenel Lateral Interbody Fusion

NCT06614296 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-10-01

No results posted yet for this study

Summary

The goal of this observational study is to learn about the readmission related to Crenel Lateral Interbody Fusion (CLIF). The main question it aims to answer is:

What are the risk factors for readmission after CLIF surgery?

Conditions

  • Spine Degeneration

Interventions

PROCEDURE

Crenel Lateral Interbody Fusion

The Crenel Lateral Interbody Fusion (CLIF) is a surgical technique developed by the Department of Spine Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine. Building on the traditional Lateral Lumbar Interbody Fusion technique, this series of technical improvements overcomes the shortcomings of previous surgical methods, enhancing the safety, operability, and effectiveness of the surgery while reducing complications.

PROCEDURE

Crenel lateral interbody fusion plus second stage surgery

The patient was first admitted to undergo CLIF surgery and was discharged after the operation. The patient will return to the hospital for a second surgery at the scheduled time.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-03
Primary Completion
2024-07-25
Completion
2024-08-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06614296 on ClinicalTrials.gov